Zobrazeno 1 - 10
of 977
pro vyhledávání: '"M, Lambertini"'
Autor:
D. Soldato, L. Arecco, E. Agostinetto, M. A. Franzoi, E. Mariamidze, S. Begijanashvili, N. Brunetti, S. Spinaci, C. Solinas, I. Vaz-Luis, A. Di Meglio, M. Lambertini
Publikováno v:
Oncology and Therapy, Vol 11, Iss 2, Pp 199-229 (2023)
Abstract Prevalence of survivors of breast cancer has been steadily increasing in the last 20 years. Currently, more than 90% of women diagnosed with early-stage breast cancer are expected to be alive at 5 years from diagnosis thanks to early detecti
Externí odkaz:
https://doaj.org/article/443a2186891f4498a419d91e113e3d30
Autor:
R. Graffeo, H.Q. Rana, F. Conforti, B. Bonanni, M.J. Cardoso, S. Paluch-Shimon, O. Pagani, A. Goldhirsch, A.H. Partridge, M. Lambertini, J.E. Garber
Publikováno v:
Breast, Vol 65, Iss , Pp 32-40 (2022)
Breast cancer risk associated with germline likely pathogenic/pathogenic variants (PV) varies by gene, often by penetrance (high >50% or moderate 20–50%), and specific locus.Germline PVs in BRCA1 and BRCA2 play important roles in the development of
Externí odkaz:
https://doaj.org/article/e44df9fcbd18407d8a8d66a00d033c2a
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract More than 10% of women diagnosed with breast cancer during reproductive age carry hereditary germline pathogenic variants in high-penetrance BRCA genes or in others genes involved in DNA repair mechanisms such as PALB2, BRIP or ATM. Anticanc
Externí odkaz:
https://doaj.org/article/22959b2e1a85485d80796d6104edc4b0
Autor:
C. Massarotti, G. Asinaro, M. G. Schiaffino, C. Ronzini, I. Vacca, M. Lambertini, P. Anserini, L. Del Mastro, A. Cagnacci
Publikováno v:
Climacteric. 26:129-134
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d79834a4da6702114143fe74857160f7
https://doi.org/10.1080/13697137.2023.2167596
https://doi.org/10.1080/13697137.2023.2167596
Autor:
I, Vaz-Luis, M, Masiero, G, Cavaletti, A, Cervantes, R T, Chlebowski, G, Curigliano, E, Felip, A R, Ferreira, P A, Ganz, J, Hegarty, J, Jeon, C, Johansen, F, Joly, K, Jordan, B, Koczwara, P, Lagergren, M, Lambertini, D, Lenihan, H, Linardou, C, Loprinzi, A H, Partridge, S, Rauh, K, Steindorf, W, van der Graaf, L, van de Poll-Franse, G, Pentheroudakis, S, Peters, G, Pravettoni
Publikováno v:
Annals of Oncology, 33(11), 1119-1133. Elsevier Ltd.
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Annals of oncology : official journal of the European Society for Medical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Background: The increased number of cancer survivors and the recognition of physical and psychosocial challenges, present from cancer diagnosis through active treatment and beyond, led to the discipline of cancer survivorship. Design and methods: Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e88db7f19ff05bd9cb5fd5c5d9a7b0a5
https://doi.org/10.1016/j.annonc.2022.07.1941
https://doi.org/10.1016/j.annonc.2022.07.1941
Publikováno v:
Journal of the European Academy of Dermatology and Venereology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b36b226b0194cb573b000d3084f8552
https://doi.org/10.1111/jdv.19160
https://doi.org/10.1111/jdv.19160
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E. de Azambuja, E. Agostinetto, M. Procter, D. Eiger, N. Pondé, S. Guillaume, D. Parlier, M. Lambertini, A. Desmet, C. Caballero, C. Aguila, G. Jerusalem, J.M. Walshe, E. Frank, J. Bines, S. Loibl, M. Piccart-Gebhart, M.S. Ewer, S. Dent, C. Plummer, T. Suter
Publikováno v:
de Azambuja, E; Agostinetto, E; Procter, M; Eiger, D; Pondé, N; Guillaume, S; Parlier, D; Lambertini, M; Desmet, A; Caballero, C; Aguila, C; Jerusalem, G; Walshe, J M; Frank, E; Bines, J; Loibl, S; Piccart-Gebhart, M; Ewer, M S; Dent, S; Plummer, C; ... (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO open, 8(1), p. 100772. BMJ 10.1016/j.esmoop.2022.100772
BACKGROUND Trastuzumab increases the incidence of cardiac events (CEs) in patients with breast cancer (BC). Dual blockade with pertuzumab (P) and trastuzumab (T) improves BC outcomes and is the standard of care for high-risk human epidermal growth fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342e6faa5d0dc99bbf51763cbc13031a
https://boris.unibe.ch/177770/1/1-s2.0-S2059702922004069-main.pdf
https://boris.unibe.ch/177770/1/1-s2.0-S2059702922004069-main.pdf
